@article{201b672cea7845f78c7c7d080fcbe62b,
title = "Multimodal imaging in RBD — present and future",
abstract = "Multimodal imaging in neurodegenerative disorders can provide insights on structural, functional and neurochemical alterations that might not be possible via clinical testing alone. New findings on multimodal imaging in idiopathic REM sleep behaviour disorder (iRBD) have implications for the relationship between iRBD, the clinical phenotype of Parkinson disease and the underlying substrate of Lewy body disease, particularly for understanding the pathophysiology and designing disease-modifying therapies.",
author = "Boeve, {Bradley F.} and Kejal Kantarci",
note = "Funding Information: B.F.B. has served as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH (UO1 NS 100620, R34 AG056639, U01 AG045390, U54 NS092089, R01 AG041797, P50 AG016574, U01 AG006786 and R44 AG 050326), the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. K.K. serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc. She receives research support from Avid Radiopharmaceuticals, Eli Lilly. She is funded by the National Institutes of Health (NIH grants: U01 NS 100620, RF1 AG 57547, P50 AG 16574, U01 AG 045390, R01 NS 80816, RF1 AG 51504, U01 AG 52943, RF1 AG5 5151, R01 AG 55121 and U01 AG 52943) and the Alzheimer{\textquoteright}s Drug Discovery Foundation (ADDF). Publisher Copyright: {\textcopyright} 2018, Springer Nature Limited.",
year = "2018",
month = oct,
day = "1",
doi = "10.1038/s41582-018-0054-3",
language = "English (US)",
volume = "14",
pages = "574--576",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "10",
}